
Court Ruling Limits Ozempic Copies in Favor of FDA, Novo Nordisk
A federal court in Texas has
The ruling, issued April 24 in the U.S. District Court for the Northern District of Texas, denied a request from the Outsourcing Facilities Association (OFA) to block the FDA's recent
That decision effectively ended a temporary allowance for pharmacies to compound semaglutide-based drugs for patients. Semaglutide is the active ingredient in Ozempic and Wegovy. Court documents remain
According to a KFF
Without the shortage designation, pharmacies may no longer produce compounded versions of semaglutide except in rare circumstances. Smaller 503A pharmacies must stop immediately, while larger outsourcing facilities have until May 22 before facing FDA enforcement.
The FDA
said in
had been in shortage since 2022 due to 'increased demand.'
Related Stories
2/24/2025
1/29/2025
Several other lawsuits regarding another popular weight loss medication called tirzepatide [brand name Zepbound and Mounjaro] are also ongoing, as its manufacturer, Eli Lilly, has taken a similar legal approach as Novo Nordisk. The FDA
In an emailed statement to The Epoch Times on Friday, the Outsourcing Facilities Association said it was 'deeply disappointed' by the court's decision.
'The U.S. District Court for the Northern District of Texas misapprehended or failed to take into consideration the clear and convincing evidence that demonstrates that the manufactured supply of semaglutide is not able to meet the enormous demand in the U.S.,' said OFA Chairman Lee H. Rosebush.
'We look forward to the opportunity to introduce this evidence again through the legal process and in discussions with the FDA. We will not stop in our efforts to ensure that patients can get access to this vital medication.'
Novo Nordisk said the ruling supports the FDA's conclusion that the supply of its brand-name semaglutide products is sufficient to meet U.S. demand.
'The court's ruling left in place FDA's prior determination that all doses of Wegovy® and Ozempic® are fully available nationwide and that Novo Nordisk's supply of these FDA-approved medicines is meeting or exceeding current and projected nationwide patient demand,' the company said in the statement.
'With the FDA's resolution of the shortage of Ozempic® and Wegovy®, as left in place by this court ruling, it is illegal under U.S. compounding laws to make or sell knockoff 'semaglutide drugs,' with rare exceptions.'
The company said it has filed 111 lawsuits in federal courts across 32 states to stop the marketing and sale of what it describes as knockoff or misbranded compounded versions.
'We are pleased the court has rejected the compounders' attempts to undermine FDA's data-based decision that the shortage of Wegovy® and Ozempic® is resolved,' said Steve Benz, Novo Nordisk's general counsel.
'FDA's determination was based on a thorough review of Novo Nordisk's stable and growing supply of these important FDA-approved medicines. With the end of the shortage of Wegovy® and Ozempic®, no patient should have to be exposed to unsafe, inauthentic 'semaglutide' drugs. Patient safety remains a top priority for Novo Nordisk, and the extensive nationwide legal actions we have taken to protect Americans from the health risks posed by illegitimate 'semaglutide' drugs are working.'
While brand-name drugs such as Ozempic and Wegovy can cost
Novo Nordisk says its legal efforts are aimed at protecting patients from unsafe or unregulated products, including those made with synthetic semaglutide from overseas suppliers, such as manufacturers in China that have not been reviewed by the FDA.
Novo Nordisk and the FDA did not respond to additional questions from The Epoch Times before publication time.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Hill
13 minutes ago
- The Hill
Trump's $1,000-per-baby investment accounts: What to know
President Trump has lauded the House-approved spending bill for the 'pro-family initiative' tucked inside the legislation, which creates investment accounts for newborn babies. 'They'll really be getting a big jump on life, especially if we get a little bit lucky with some of the numbers and the economy,' Trump said at a Monday event at the White House that touted the accounts. The 'Big, Beautiful Bill' lays out rules for the Trump accounts. To qualify, a child must be a U.S. citizen, born within the next four years to at least one parent with a Social Security number. The money could be withdrawn starting at age 18. Here's what you need to know about the proposed federal program: Under the current bill text, the program would be available to families of all income levels, with babies born after Dec. 31, 2024, and before Jan. 1, 2029. A one-time $1,000 contribution would be provided by the Treasury Department and deposited into a diversified U.S. stock index fund or its equivalent. Families, guardians and private entities will be able to contribute no more than $5,000 per year to the account. An estimated 7 percent return on the $1,000 would compound to roughly $3,570 over 18 years, according to the Associated Press. The legislation does not provide a limit on the amount of money a nonprofit or company can donate to a child's investment account within the $5,000 annual contribution limit. Several businesses, including Uber, Dell, Goldman Sachs and Altimeter have committed to setting aside billions to invest in the accounts of company employees who become new parents. 'It's not just an account; it's a launchpad. It puts the unstoppable engine of compounding to work for our kids, building a future for them from day one,' Uber CEO Dara Khosrowshahi said about the initiative during a White House roundtable. Children enrolled in the investment program are eligible to withdraw half of the cash value amount between their 18th and 25th birthdays, according to CNN. Families and beneficiaries would pay a penalty for early withdrawal as there is no allowance for emergency use of the funds, the outlet reported. Funds withdrawn for anything other than 'qualified expenses,' including paying for higher education, buying a residence or starting a business, will be taxed. Researchers have said the investment accounts could widen America's wealth gap. 'Under the current proposal, every child starts with the same amount, and families can contribute up to $5,000 annually,' the Urban Institute, a think-tank focused on social policy, wrote in a late May report. 'But relatively few households hold substantial liquid wealth in the United States, meaning higher-income households are far more likely than their lower-income counterparts to have the means to contribute additional funds,' it continued. The study noted that Trump accounts are likely to only benefit those who have already maxed out existing tax-preferred savings opportunities, like 529 accounts. Instead, they suggested low income families with job insecurity are more likely to gravitate towards investing in traditional accounts that offer flexible guidelines. Trump's 'One Big, Beautiful Bill' still needs approval from the upper chamber. Senators considering potential changes or cuts to the legislation, hoping to pass the bill before July 4.
Yahoo
19 minutes ago
- Yahoo
TriMas Aerospace to Exhibit at the 2025 Paris Air Show
TriMas Aerospace Booth Located at Hall 4, Stand D-194 BLOOMFIELD HILLS, Mich., June 10, 2025--(BUSINESS WIRE)--TriMas Aerospace, a division of TriMas (NASDAQ: TRS), will be exhibiting at the 2025 International Paris Air Show, taking place June 16-22 at Le Bourget in Paris, France. As one of the world's premier aerospace exhibitions, the Paris Air Show brings together industry leaders, innovators and partners from around the globe. TriMas Aerospace returns to the Paris Air Show to unveil new products, reinforce its global position through the recent acquisition of GMT Aerospace and introduce Norris Cylinder's aerospace offering at the event. "We're excited to return to the Paris Air Show to connect with key OEMs, distribution partners and suppliers to discuss collaborative opportunities and demonstrate our expanded capabilities," said Vitaliy Rusakov, President, TriMas Aerospace. "This event is an important platform to demonstrate our latest technologies, align with customer needs, and explore new ways to strengthen supply chain efficiency and innovation." During the Air Show, TriMas Aerospace will highlight a range of new products, including advanced fastening systems, and precision-machined and welded components designed for both commercial and military aerospace applications, developed in close collaboration with customer technical teams. These products reflect TriMas Aerospace's commitment to delivering high-quality, engineered solutions that meet the industry's most stringent standards. Attendees can explore these innovations at the TriMas Aerospace booth, showcasing brands such as Monogram Aerospace Fasteners™, Allfast Fastening Systems®, Mac Fasteners™ and RSA Engineered Products™. The recent acquisition of GMT Aerospace, renamed TriMas Aerospace Germany (TAG), solidifies TriMas Aerospace's position as a leading global player in the aerospace and defense sectors. TAG's expertise in highly-engineered tie-rods and rubber-metal anti-vibration systems complements TriMas Aerospace's portfolio, enhancing its ability to serve customers worldwide. "Integrating TAG expands our manufacturing footprint into Europe and strengthens our relationships with key suppliers and OEMs," continued Rusakov. "This strategic move positions us to deliver even greater value to our global customers." TriMas' Norris Cylinder business, a leading manufacturer of high- and low-pressure steel cylinders, will join the TriMas Aerospace group at the Paris Air Show to help expand its aerospace and defense portfolio. Norris Cylinder's expertise in compressed gas solutions complements TriMas Aerospace's offerings, providing new opportunities to address the evolving needs of the aerospace market. "We are excited to introduce Norris Cylinder's capabilities to our aerospace customers, further diversifying our portfolio and reinforcing our commitment to innovation," added Rusakov. About TriMas Aerospace TriMas Aerospace specializes in the design and manufacture of highly-engineered fasteners and precision-machined components, serving commercial aircraft manufacturers and the U.S. military. Through its portfolio of trusted brands, Monogram Aerospace Fasteners™, Allfast Fastening Systems®, Mac Fasteners™, TFI Aerospace, TAG, Martinic Engineering™, RSA Engineered Products™, and Weldmac Manufacturing Company, TriMas Aerospace delivers innovative solutions that meet the most stringent industry standards. The Company's advanced fastener offering includes blind bolts, solid and blind rivets, temporary fasteners, collars and standard fasteners, designed for composite and metallic aircraft structures. TriMas Aerospace also provides cutting-edge air ducting products and precision-machined components, engineered to deliver exceptional quality, reliability and performance across a wide range of aerospace applications. For more information, please visit About TriMas TriMas manufactures a diverse set of products primarily for the consumer products, aerospace and industrial markets through its TriMas Packaging, TriMas Aerospace and Specialty Products groups. Our approximately 3,900 dedicated employees in 13 countries provide customers with a wide range of innovative and quality product solutions through our market-leading businesses. Our TriMas family of businesses has strong brand names in the markets served, and operates under a common set of values and strategic priorities under the TriMas Business Model. TriMas is publicly traded on the NASDAQ under the ticker symbol "TRS," and is headquartered in Bloomfield Hills, Michigan. For more information, please visit View source version on Contacts Sherry LauderbackVP, Investor Relations, Communications & Sustainability(248) Sign in to access your portfolio
Yahoo
20 minutes ago
- Yahoo
Novo Nordisk Stock Climbs on Report of Activist Investor Parvus Building Stake
Novo Nordisk stock rose on Tuesday after the Financial Times reported that an activist investor is building a stake in the Danish drugmaker. Parvus Asset Management is reportedly looking to influence the hiring of Novo Nordisk's next CEO, the FT reported. The Ozempic and Wegovy maker has faced slowing sales growth and more effective rival weight loss drugs, and it announced last month that its CEO is U.S.-listed shares of Danish drugmaker Novo Nordisk (NVO) rose Tuesday following a report that an activist investor is building a stake in the Ozempic maker. Citing sources familiar with the matter, the Financial Times reported on Monday that Parvus Asset Management has bought up shares in Novo Nordisk, and is looking to influence the hiring of the drugmaker's next CEO. The fund has not disclosed the size of its stake because it is still under 5% of Novo Nordisk's total shares, the legal threshold requiring disclosure under Danish law, the Financial Times reported. The Novo Nordisk Foundation nonprofit owns the majority of voting rights in the weight loss giant, which the FT reported could make any activist pressure campaign difficult. Novo Nordisk's U.S.-listed shares have lost nearly half their value in the last 12 months as sales growth for its landmark weight loss drugs Ozempic and Wegovy have started to slow. Studies have also shown that Eli Lilly's (LLY) rival drugs, Mounjaro and Zepbound, are more effective at weight loss along with promising data for its next-generation drugs. Last month, Novo Nordisk cut its full-year sales and profit forecasts, and just over a week later announced that CEO Lars Fruergaard Jørgensen would step away from the company once it found a successor. Novo Nordisk and Parvus did not immediately respond to Investopedia's requests for comment. Novo Nordisk's American depositary shares were up more than 5% in Tuesday morning trading. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data